HER2-negative breast cancer
New Strategy Proposed for HR+, HER2– Advanced Breast Cancer
In certain patients with HR+, HER2– advanced breast cancer, switching from an aromatase inhibitor to ...
AUGUST 26, 2025
Olaparib Now Indicated for Adjuvant Treatment of High-Risk Early Breast Cancer
The FDA approved olaparib (Lynparza, AstraZeneca) as an adjuvant treatment for adults with germline BRCA-mutated, ...
MARCH 17, 2022
Adding Palbociclib to Endocrine Therapy Shows No Benefit in Study
There is no benefit to adding palbociclib to endocrine therapy in patients with early hormone receptor ...
MARCH 16, 2022
PGx Test May Spare Breast Cancer Chemotherapy
Women with HR-positive, HER2-negative breast cancer who are at a midrange risk by genomic scoring can forgo ...
JANUARY 8, 2019
FDA Approves Talzenna for gBRCAm HER2-Negative Breast Cancer
The FDA approved Talzenna, a poly(adenosine diphosphate–ribose) polymerase inhibitor, for patients with ...
OCTOBER 16, 2018
FDA Approves Kisqali Femara Co-Pack
The co-pack is the first, and only currently available, combination pack with two prescription products for ...
MAY 10, 2017
